

cfw 1653  
\$

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

INFORMATION DISCLOSURE  
STATEMENT

Patent Application  
Docket No. BB-112T  
Serial No. 09/641,104

January 7, 2005

David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1653  
Applicant(s) : Walter Birchmeier, Jens-Peter Von Kries  
Serial No. : 09/641,104  
Filed : August 17, 2000  
Conf. No. : 5225  
For : Agents for Treating Human Illnesses, Based on Beta Catenin, and the  
Production and Use Thereof

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Most of the cited documents are patents so the applicants have not enclosed full copies of these documents; however, the applicant is enclosing a copy of the first sheet of each patent document and a full copy of the non

H:\doc\ids\BB-112T-IDScover.doc\DNB/lj

01/11/2005 EFLDRES 00000159 190065 09641104

01 FC:1806 180.00 DA

patent literature document. Also enclosed is a copy of the International Search Report in which these documents were cited in a related international application.


It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first office action on the merits, but before the mailing of a final action or the notice of allowance.

The applicants hereby authorize charge of \$180.00 to Deposit Account No. 19-0065. The Commissioner is hereby authorized to charge any additional fees which may be required to Deposit Account No. 19-0065.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,




David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

DRS/lj

Attachments: Form PTO/SB/08  
Copies of cited references listed thereon  
International Search Report

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete if Known

Application Number	09/641,104
Filing Date	August 17, 2000
First Named Inventor	Walter Birchmeier
Group Art Unit	1653
Examiner Name	Chih Min Kam
Attorney Docket Number	BB-112T

Sheet 2 of 2

### OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	TETSU O and MCCORMICK F, "Beta-Catenin regulates expression of cyclin D1 in colon carcinoma cells" <i>Nature</i> (1999), vol. 398, pages 422-426.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner  
Signature


Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	09/641,104
Filing Date	August 17, 2000
First Named Inventor	Walter Birchmeier
Group Art Unit	1653
Examiner Name	Chih Min Kam
Attorney Docket Number	BB-112T

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	U1					
	U2					
	U3					
	U4					
	U5					

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Code <sup>5</sup> Office <sup>3</sup> known	Number <sup>4</sup>	Kind (if known)				
	F1		EP 0757994	B1	Snow Brand Milk Prod. Co., Ltd.	02-12-1997		
	F2		WO 96/16170		Eisai Co., Ltd.	05-30-1996		
	F3		WO 98/45319		McGill University	10-15-1998		
	F4		WO 9842296		Onyx Pharmaceuticals Inc.	10-01-1998		
	F5		WO 98/41631		Utrecht Univ. John Hopkins Univ.	09-24-1998		
	F6		WO 96/16170	A	Eisai Co. LTD	05-30-1996-		
	F7							
	F8							

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.